New combo shot targets obesity in early trial
NCT ID NCT06972992
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 24 times
Summary
This early-stage study tested a new drug called ASC47, given as a shot under the skin, together with semaglutide (a weight-loss medication) in 28 adults with obesity. The main goal was to check safety and side effects, and researchers also looked at changes in body weight over 10 weeks. The study was completed and used a placebo group for comparison.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC WEIGHT MANAGEMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascletis Clinical Site
San Antonio, Texas, 78209, United States
Conditions
Explore the condition pages connected to this study.